Shanghai Pharmaceuticals gains control of Shanghai Hutchison Pharma

Shanghai Pharmaceuticals Holding (SSE:601607) has successfully completed its acquisition of a 10% equity interest in Shanghai Hutchison Pharmaceuticals, announced December 31, 2024. This transaction, finalized on April 25, allows Shanghai Pharmaceuticals to consolidate its holdings to 60% and exercise control over Shanghai Hutchison Pharmaceuticals. As part of the deal, Shanghai Jinpu Funds acquired 25.1247%, and Shanghai Jinpu Zhiliai acquired 9.8753% of Shanghai Hutchison Pharmaceuticals’ equity. In other news, subsidiary Shanghai Shangyao Zhongxi Pharmaceutical has received approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for valganciclovir hydrochloride tablets, for which the company has spent approximately CNY1,529,940. Valganciclovir hydrochloride tablets are indicated for treating cytomegalovirus (CMV) retinitis in adults with acquired immunodeficiency syndrome (AIDS) and for the prevention of CMV infection in solid organ transplant recipients.